Outbuildings
Outbuildings are small buildings for keeping things in or working in which are near a house, on t ... Read More
Global Drugs for Vulvovaginal Candidiasis Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2031
1 Study Coverage
1.1 Drugs for Vulvovaginal Candidiasis Product Introduction
1.2 Market by Type
1.2.1 Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Type
1.2.2 Cream
1.2.3 Pessary
1.2.4 Other
1.3 Market by Application
1.3.1 Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Application
1.3.2 Hospital & Clinic
1.3.3 Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Drugs for Vulvovaginal Candidiasis Market Size Estimates and Forecasts
2.1.1 Global Drugs for Vulvovaginal Candidiasis Revenue 2016-2027
2.1.2 Global Drugs for Vulvovaginal Candidiasis Sales 2016-2027
2.2 Drugs for Vulvovaginal Candidiasis Market Size by Region: 2021 Versus 2027
2.3 Drugs for Vulvovaginal Candidiasis Sales by Region (2016-2027)
2.3.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2016-2021
2.3.2 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Region (2022-2027)
2.3.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2016-2027)
2.4 Drugs for Vulvovaginal Candidiasis Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2016-2021
2.4.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region (2022-2027)
2.4.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2016-2027)
3 Global Drugs for Vulvovaginal Candidiasis by Manufacturers
3.1 Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Sales
3.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2021)
3.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Revenue
3.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2021)
3.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturer (2016-2021)
3.3 Global Drugs for Vulvovaginal Candidiasis Price by Manufacturer (2016-2021)
3.4 Competitive Landscape
3.4.1 Key Drugs for Vulvovaginal Candidiasis Manufacturers Covered: Ranking by Revenue
3.4.2 Global Drugs for Vulvovaginal Candidiasis Market Concentration Ratio (CR5 and HHI) & (2016-2021)
3.4.3 Global Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution, Product Type
3.5.1 Drugs for Vulvovaginal Candidiasis Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
3.5.3 Date of International Manufacturers Enter into Drugs for Vulvovaginal Candidiasis Market
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Bayer
4.1.1 Bayer Corporation Information
4.1.2 Bayer Description, Business Overview
4.1.3 Bayer Drugs for Vulvovaginal Candidiasis Products Offered
4.1.4 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.1.5 Bayer Drugs for Vulvovaginal Candidiasis Revenue by Product
4.1.6 Bayer Drugs for Vulvovaginal Candidiasis Revenue by Application
4.1.7 Bayer Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.1.8 Bayer Drugs for Vulvovaginal Candidiasis Revenue by Sales Channel
4.1.9 Bayer Recent Development
4.2 Perrigo
4.2.1 Perrigo Corporation Information
4.2.2 Perrigo Description, Business Overview
4.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Products Offered
4.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.2.5 Perrigo Drugs for Vulvovaginal Candidiasis Revenue by Product
4.2.6 Perrigo Drugs for Vulvovaginal Candidiasis Revenue by Application
4.2.7 Perrigo Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.2.8 Perrigo Drugs for Vulvovaginal Candidiasis Revenue by Sales Channel
4.2.9 Perrigo Recent Development
4.3 J & J
4.3.1 J & J Corporation Information
4.3.2 J & J Description, Business Overview
4.3.3 J & J Drugs for Vulvovaginal Candidiasis Products Offered
4.3.4 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.3.5 J & J Drugs for Vulvovaginal Candidiasis Revenue by Product
4.3.6 J & J Drugs for Vulvovaginal Candidiasis Revenue by Application
4.3.7 J & J Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.3.8 J & J Drugs for Vulvovaginal Candidiasis Revenue by Sales Channel
4.3.9 J & J Recent Development
4.4 Pfizer
4.4.1 Pfizer Corporation Information
4.4.2 Pfizer Description, Business Overview
4.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Products Offered
4.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.4.5 Pfizer Drugs for Vulvovaginal Candidiasis Revenue by Product
4.4.6 Pfizer Drugs for Vulvovaginal Candidiasis Revenue by Application
4.4.7 Pfizer Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.4.8 Pfizer Drugs for Vulvovaginal Candidiasis Revenue by Sales Channel
4.4.9 Pfizer Recent Development
4.5 Bristol-Myers Squibb
4.5.1 Bristol-Myers Squibb Corporation Information
4.5.2 Bristol-Myers Squibb Description, Business Overview
4.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Products Offered
4.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.5.5 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue by Product
4.5.6 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue by Application
4.5.7 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.5.8 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue by Sales Channel
4.5.9 Bristol-Myers Squibb Recent Development
4.6 Effik
4.6.1 Effik Corporation Information
4.6.2 Effik Description, Business Overview
4.6.3 Effik Drugs for Vulvovaginal Candidiasis Products Offered
4.6.4 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.6.5 Effik Drugs for Vulvovaginal Candidiasis Revenue by Product
4.6.6 Effik Drugs for Vulvovaginal Candidiasis Revenue by Application
4.6.7 Effik Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.6.8 Effik Recent Development
4.7 Teva
4.7.1 Teva Corporation Information
4.7.2 Teva Description, Business Overview
4.7.3 Teva Drugs for Vulvovaginal Candidiasis Products Offered
4.7.4 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.7.5 Teva Drugs for Vulvovaginal Candidiasis Revenue by Product
4.7.6 Teva Drugs for Vulvovaginal Candidiasis Revenue by Application
4.7.7 Teva Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.7.8 Teva Recent Development
4.8 Sanofi
4.8.1 Sanofi Corporation Information
4.8.2 Sanofi Description, Business Overview
4.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Products Offered
4.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.8.5 Sanofi Drugs for Vulvovaginal Candidiasis Revenue by Product
4.8.6 Sanofi Drugs for Vulvovaginal Candidiasis Revenue by Application
4.8.7 Sanofi Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.8.8 Sanofi Recent Development
4.9 Cisen Pharmaceutical
4.9.1 Cisen Pharmaceutical Corporation Information
4.9.2 Cisen Pharmaceutical Description, Business Overview
4.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Products Offered
4.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.9.5 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Revenue by Product
4.9.6 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Revenue by Application
4.9.7 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.9.8 Cisen Pharmaceutical Recent Development
4.10 Kingyork Group
4.10.1 Kingyork Group Corporation Information
4.10.2 Kingyork Group Description, Business Overview
4.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Products Offered
4.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.10.5 Kingyork Group Drugs for Vulvovaginal Candidiasis Revenue by Product
4.10.6 Kingyork Group Drugs for Vulvovaginal Candidiasis Revenue by Application
4.10.7 Kingyork Group Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.10.8 Kingyork Group Recent Development
5 Breakdown Data by Type
5.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2027)
5.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021)
5.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2022-2027)
5.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2027)
5.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Type (2016-2027)
5.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2016-2021)
5.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Type (2022-2027)
5.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2016-2027)
5.3 Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Type (2016-2027)
6 Breakdown Data by Application
6.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2027)
6.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021)
6.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2022-2027)
6.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2027)
6.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Application (2016-2027)
6.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2016-2021)
6.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Application (2022-2027)
6.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2016-2027)
6.3 Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Application (2016-2027)
7 North America
7.1 North America Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
7.2 North America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
7.2.1 North America Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2027)
7.2.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2027)
7.3 North America Drugs for Vulvovaginal Candidiasis Sales by Type
7.4 North America Drugs for Vulvovaginal Candidiasis Sales by Application
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
8.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Region
8.2.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2016-2027)
8.2.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2016-2027)
8.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Type
8.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Application
9 Europe
9.1 Europe Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
9.2 Europe Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
9.2.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2027)
9.2.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2027)
9.3 Europe Drugs for Vulvovaginal Candidiasis Sales by Type
9.4 Europe Drugs for Vulvovaginal Candidiasis Sales by Application
10 Latin America
10.1 Latin America Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
10.2 Latin America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
10.2.1 Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2027)
10.2.2 Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2027)
10.3 Latin America Drugs for Vulvovaginal Candidiasis Sales by Type
10.4 Latin America Drugs for Vulvovaginal Candidiasis Sales by Application
11 Middle East and Africa
11.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
11.2.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2027)
11.2.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2027)
11.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Type
11.4 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Application
12 Supply Chain and Sales Channel Analysis
12.1 Drugs for Vulvovaginal Candidiasis Supply Chain Analysis
12.2 Drugs for Vulvovaginal Candidiasis Key Raw Materials and Upstream Suppliers
12.3 Drugs for Vulvovaginal Candidiasis Clients Analysis
12.4 Drugs for Vulvovaginal Candidiasis Sales Channel and Sales Model Analysis
12.4.1 Drugs for Vulvovaginal Candidiasis Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Drugs for Vulvovaginal Candidiasis Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Drugs for Vulvovaginal Candidiasis Distributors
13 Market Dynamics
13.1 Drugs for Vulvovaginal Candidiasis Market Drivers
13.2 Drugs for Vulvovaginal Candidiasis Market Opportunities
13.3 Drugs for Vulvovaginal Candidiasis Market Challenges
13.4 Drugs for Vulvovaginal Candidiasis Market Restraints
13.5 Porter’s Five Forces Analysis
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Type (US$ Million): 2021 VS 2027
Table 2. Major Manufacturers of Cream
Table 3. Major Manufacturers of Pessary
Table 4. Major Manufacturers of Other
Table 5. Global Drugs for Vulvovaginal Candidiasis Market Size Growth by Application (US$ Million): 2021 VS 2027
Table 6. Global Drugs for Vulvovaginal Candidiasis Market Size by Region (US$ Million): 2021 VS 2027
Table 7. Global Drugs for Vulvovaginal Candidiasis Sales by Region (2016-2021) & (K Units)
Table 8. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Region (2022-2027) & (K Units)
Table 9. Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2016-2021) & (US$ Million)
Table 10. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 11. Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2021) & (K Units)
Table 12. Global Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturer (2016-2021)
Table 13. Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2021) & (US$ Million)
Table 14. Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturer (2016-2021)
Table 15. Key Manufacturers Drugs for Vulvovaginal Candidiasis Price (2016-2021) & (USD/Unit)
Table 16. Ranking of Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Revenue (US$ Million) in 2020
Table 17. Global Drugs for Vulvovaginal Candidiasis Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 18. Global Drugs for Vulvovaginal Candidiasis by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2020)
Table 19. Drugs for Vulvovaginal Candidiasis Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
Table 21. Date of International Manufacturers Enter into Drugs for Vulvovaginal Candidiasis Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Bayer Corporation Information
Table 24. Bayer Description and Business Overview
Table 25. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 26. Bayer Drugs for Vulvovaginal Candidiasis Product
Table 27. Bayer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 28. Bayer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 29. Bayer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 30. Bayer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Sales Channel
Table 31. Bayer Recent Development
Table 32. Perrigo Corporation Information
Table 33. Perrigo Description and Business Overview
Table 34. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 35. Perrigo Drugs for Vulvovaginal Candidiasis Product
Table 36. Perrigo Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 37. Perrigo Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 38. Perrigo Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 39. Perrigo Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Sales Channel
Table 40. Perrigo Recent Development
Table 41. J & J Corporation Information
Table 42. J & J Description and Business Overview
Table 43. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 44. J & J Drugs for Vulvovaginal Candidiasis Product
Table 45. J & J Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 46. J & J Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 47. J & J Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 48. J & J Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Sales Channel
Table 49. J & J Recent Development
Table 50. Pfizer Corporation Information
Table 51. Pfizer Description and Business Overview
Table 52. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 53. Pfizer Drugs for Vulvovaginal Candidiasis Product
Table 54. Pfizer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 55. Pfizer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 56. Pfizer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 57. Pfizer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Sales Channel
Table 58. Pfizer Recent Development
Table 59. Bristol-Myers Squibb Corporation Information
Table 60. Bristol-Myers Squibb Description and Business Overview
Table 61. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 62. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product
Table 63. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 64. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 65. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 66. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Sales Channel
Table 67. Bristol-Myers Squibb Recent Development
Table 68. Effik Corporation Information
Table 69. Effik Description and Business Overview
Table 70. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 71. Effik Drugs for Vulvovaginal Candidiasis Product
Table 72. Effik Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 73. Effik Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 74. Effik Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 75. Effik Recent Development
Table 76. Teva Corporation Information
Table 77. Teva Description and Business Overview
Table 78. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 79. Teva Drugs for Vulvovaginal Candidiasis Product
Table 80. Teva Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 81. Teva Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 82. Teva Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 83. Teva Recent Development
Table 84. Sanofi Corporation Information
Table 85. Sanofi Description and Business Overview
Table 86. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 87. Sanofi Drugs for Vulvovaginal Candidiasis Product
Table 88. Sanofi Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 89. Sanofi Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 90. Sanofi Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 91. Sanofi Recent Development
Table 92. Cisen Pharmaceutical Corporation Information
Table 93. Cisen Pharmaceutical Description and Business Overview
Table 94. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 95. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product
Table 96. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 97. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 98. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 99. Cisen Pharmaceutical Recent Development
Table 100. Kingyork Group Corporation Information
Table 101. Kingyork Group Description and Business Overview
Table 102. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 103. Kingyork Group Drugs for Vulvovaginal Candidiasis Product
Table 104. Kingyork Group Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 105. Kingyork Group Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 106. Kingyork Group Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 107. Kingyork Group Recent Development
Table 108. Global Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 109. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2022-2027) & (K Units)
Table 110. Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2016-2021) & (US$ Million)
Table 111. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 112. Global Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 113. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2022-2027) & (K Units)
Table 114. Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2016-2021) & (US$ Million)
Table 115. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 116. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021) & (K Units)
Table 117. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2022-2027) & (K Units)
Table 118. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021) & (US$ Million)
Table 119. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2022-2027) & (US$ Million)
Table 120. North America Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 121. North America Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 122. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2016-2021) & (K Units)
Table 123. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2022-2027) & (K Units)
Table 124. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2016-2027) & (US$ Million)
Table 125. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2022-2027) & (US$ Million)
Table 126. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 127. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 128. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021) & (K Units)
Table 129. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2022-2027) & (K Units)
Table 130. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021) & (US$ Million)
Table 131. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2022-2027) & (US$ Million)
Table 132. Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 133. Europe Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 134. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021) & (K Units)
Table 135. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2022-2027) & (K Units)
Table 136. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021) & (US$ Million)
Table 137. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2022-2027) & (US$ Million)
Table 138. Latin America Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 139. Latin America Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 140. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021) & (K Units)
Table 141. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2022-2027) & (K Units)
Table 142. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021) & (US$ Million)
Table 143. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2022-2027) & (US$ Million)
Table 144. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 145. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 146. Drugs for Vulvovaginal Candidiasis Key Raw Materials, Industry Status and Trend
Table 147. Drugs for Vulvovaginal Candidiasis Key Raw Materials and Upstream Suppliers
Table 148. Drugs for Vulvovaginal Candidiasis Clients Status and Trend
Table 149. Drugs for Vulvovaginal Candidiasis Typical Clients
Table 150. Drugs for Vulvovaginal Candidiasis Distributors
Table 151. Key Drivers: Impact Analysis (2022-2027)
Table 152. Drugs for Vulvovaginal Candidiasis Market Drivers
Table 153. Drugs for Vulvovaginal Candidiasis Market Opportunities
Table 154. Drugs for Vulvovaginal Candidiasis Market Challenges
Table 155. Drugs for Vulvovaginal Candidiasis Market Restraints
Table 156. Drugs for Vulvovaginal Candidiasis Porter’s Five Forces Analysis
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Drugs for Vulvovaginal Candidiasis Product Picture
Figure 2. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2021 & 2027
Figure 3. Cream Product Picture
Figure 4. Pessary Product Picture
Figure 5. Other Product Picture
Figure 6. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2021 & 2027
Figure 7. Hospital & Clinic Examples
Figure 8. Pharmacy Examples
Figure 9. Drugs for Vulvovaginal Candidiasis Report Years Considered
Figure 10. Global Drugs for Vulvovaginal Candidiasis Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Drugs for Vulvovaginal Candidiasis Market Size 2016-2027 (US$ Million)
Figure 12. Global Drugs for Vulvovaginal Candidiasis Sales 2016-2027 (K Units)
Figure 13. Global Drugs for Vulvovaginal Candidiasis Market Size Market Share by Region: 2021 Versus 2027
Figure 14. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Region (2016-2027)
Figure 15. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2016-2027)
Figure 16. Global Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturer in 2020
Figure 17. Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 18. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Type (2016-2027)
Figure 19. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Type (2016-2027)
Figure 20. Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit)
Figure 21. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Application (2016-2027)
Figure 22. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Application (2016-2027)
Figure 23. Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Application (2016-2021) & (USD/Unit)
Figure 24. North America Drugs for Vulvovaginal Candidiasis Revenue 2016-2027 (US$ Million)
Figure 25. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
Figure 26. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
Figure 27. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue 2016-2027 (US$ Million)
Figure 28. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2016-2027)
Figure 29. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2016-2027)
Figure 30. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
Figure 31. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
Figure 32. Europe Drugs for Vulvovaginal Candidiasis Revenue Growth Rate 2016-2027 (US$ Million)
Figure 33. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2016-2027)
Figure 34. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2016-2027)
Figure 35. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
Figure 36. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
Figure 37. Latin America Drugs for Vulvovaginal Candidiasis Revenue Growth Rate 2016-2027 (US$ Million)
Figure 38. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2016-2027)
Figure 39. Latin America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2016-2021)
Figure 40. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
Figure 41. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
Figure 42. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Growth Rate 2016-2027 (US$ Million)
Figure 43. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2016-2027)
Figure 44. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2016-2027)
Figure 45. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
Figure 46. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
Figure 47. Drugs for Vulvovaginal Candidiasis Supply Chain (Upstream and Downstream Market)
Figure 48. Global Production Market Share of Drugs for Vulvovaginal Candidiasis Raw Materials by Region in 2020
Figure 49. Drugs for Vulvovaginal Candidiasis Distribution Channels
Figure 50. Global Drugs for Vulvovaginal Candidiasis Percentage 2016-2027: Indirect Sales VS Direct Sales
Figure 51. Global Drugs for Vulvovaginal Candidiasis Percentage 2016-2027: Online Sales VS Offline Sales
Figure 52. Porter's Five Forces Analysis
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Bayer Perrigo J & J Pfizer Bristol-Myers Squibb Effik Teva Sanofi Cisen Pharmaceutical Kingyork Group